Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18614062 | CAREGIVER SYSTEM AND METHOD FOR INTERFACING WITH AND CONTROLLING A MEDICATION DISPENSING DEVICE | March 2024 | May 2025 | Allow | 14 | 3 | 0 | Yes | No |
| 18469433 | REMOTE DIAGNOSTIC TESTING AND TREATMENT | September 2023 | January 2026 | Abandon | 28 | 1 | 0 | No | No |
| 18278215 | A Privacy Enabled System And Method For Managing Logistics For Clinical Study Participants | August 2023 | January 2026 | Abandon | 29 | 1 | 0 | No | No |
| 18230328 | METHODS AND SYSTEMS FOR CONDUCTING PREGNANCY-RELATED CLINICAL TRIALS | August 2023 | December 2025 | Abandon | 29 | 1 | 0 | No | No |
| 18219683 | MAPPING BIOMEDICAL ENTITIES | July 2023 | November 2025 | Abandon | 29 | 1 | 0 | No | No |
| 18336125 | METHODS FOR QUALITY OF LIFE ASSESSMENT IN COMPANION ANIMALS | June 2023 | February 2026 | Abandon | 32 | 2 | 0 | No | No |
| 18325980 | INFORMATION PROCESSING APPARATUS, INFORMATION PROCESSING METHOD, AND PROGRAM | May 2023 | December 2025 | Abandon | 31 | 2 | 0 | No | No |
| 18168210 | REMOTE DIAGNOSTIC TESTING AND TREATMENT | February 2023 | September 2025 | Abandon | 31 | 1 | 0 | No | No |
| 18101372 | SYSTEM AND METHOD FOR PROVIDING REAL-TIME PRESCRIPTION SHARING AND DISPENSING INFORMATION MONITORING SERVICE BASED ON BLOCKCHAIN NETWORK | January 2023 | September 2025 | Abandon | 32 | 1 | 0 | No | No |
| 18089593 | AI-BASED CUSTOMIZED MEDICAL INFORMATION PROVISION SYSTEM AND METHOD | December 2022 | September 2025 | Abandon | 33 | 1 | 0 | No | No |
| 17755516 | METHOD AND SYSTEM FOR BLOCKCHAIN-BASED MEDICINE-TAKING MANAGEMENT FOR CLINICAL TRIAL SUBJECT | December 2022 | August 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17913203 | IDENTIFYING HIGH COST IMAGING PROCEDURES HAVING SCOPE FOR OPERATIONAL AND FINANCIAL IMPROVEMENT | September 2022 | June 2025 | Abandon | 33 | 1 | 0 | No | No |
| 17941898 | SINGLE BARCODE SCAN CAST SYSTEM FOR PHARMACEUTICAL PRODUCTS | September 2022 | January 2026 | Allow | 40 | 2 | 0 | Yes | No |
| 17939947 | SYSTEM FOR PROVIDING HEALTH INFORMATION THROUGH CUSTOMIZED SEARCH THAT REFLECTS INDIVIDUAL HEALTH CONDITIONS, AND OPERATION METHOD THEREOF | September 2022 | April 2025 | Abandon | 32 | 1 | 0 | No | No |
| 17882070 | SYSTEM AND METHOD FOR IDENTIFYING TREATABLE AND REMEDIABLE FACTORS OF DEMENTIA AND AGING COGNITIVE CHANGES | August 2022 | October 2025 | Abandon | 38 | 2 | 0 | No | No |
| 17866286 | INTELLIGENT MEDICAL ASSESSMENT AND COMMUNICATION SYSTEM WITH ARTIFICIAL INTELLIGENCE | July 2022 | September 2025 | Allow | 38 | 2 | 0 | Yes | No |
| 17865250 | System and Method of Facilitating Digital Therapy for Long-Term Neuropsychological Rehabilitation | July 2022 | December 2024 | Abandon | 29 | 1 | 0 | No | No |
| 17660573 | Electronic Prescription System | April 2022 | October 2024 | Abandon | 30 | 1 | 0 | No | No |
| 17724908 | REFERENTIAL DATA GROUPING AND TOKENIZATION FOR LONGITUDINAL USE OF DE-IDENTIFIED DATA | April 2022 | March 2025 | Allow | 35 | 3 | 0 | Yes | No |
| 17655515 | METHOD FOR RECOMMENDING CONTINUING EDUCATION TO HEALTH PROFESSIONALS BASED ON PATIENT OUTCOMES | March 2022 | September 2024 | Allow | 30 | 1 | 0 | No | No |
| 17687326 | SYSTEM, METHOD, AND APPARATUS FOR PROVIDING REMOTE HEALTHCARE | March 2022 | October 2024 | Abandon | 31 | 1 | 0 | No | No |
| 17674323 | ELECTRONIC HEALTH RECORD INTEROPERABILITY TOOL | February 2022 | June 2025 | Allow | 40 | 2 | 0 | No | No |
| 17634277 | PATIENT-BASED DIETARY PLAN RECOMMENDATION SYSTEM | February 2022 | June 2025 | Abandon | 41 | 3 | 0 | Yes | No |
| 17669171 | SYSTEMS AND METHODS FOR SIGNALING COGNITIVE-STATE TRANSITIONS | February 2022 | February 2025 | Abandon | 36 | 2 | 0 | Yes | No |
| 17381954 | PERSONAL AND CORPORATE PATHOGEN-RISK ASSESSMENT WITH PANDEMIC-BIO-SURVEILLANCE MULTI PATHOGEN SYSTEMS | July 2021 | February 2025 | Abandon | 42 | 2 | 0 | No | Yes |
| 17215044 | DIAGNOSTIC DEVICE FOR REMOTE CONSULTATIONS AND TELEMEDICINE | March 2021 | August 2024 | Allow | 41 | 5 | 0 | Yes | Yes |
| 17194073 | HEALTH MONITORING SYSTEM SUPPORTING CONFIGURABLE HEALTH STUDIES | March 2021 | April 2025 | Abandon | 49 | 5 | 0 | No | No |
| 17183741 | INTERACTIVE SURGICAL SYSTEMS WITH ENCRYPTED COMMUNICATION CAPABILITIES | February 2021 | December 2025 | Abandon | 58 | 4 | 0 | Yes | No |
| 17163429 | TRIAL DESIGN WITH CONVEX-HULL TECHNIQUES | January 2021 | October 2024 | Abandon | 45 | 2 | 0 | Yes | No |
| 17163432 | ROBUST TRIAL DESIGN PLATFORM | January 2021 | November 2024 | Abandon | 46 | 4 | 0 | Yes | No |
| 17100324 | GENERATING DYNAMIC ELECTRONIC USER NOTIFICATIONS TO FACILITATE SAFE PRESCRIPTION USE | November 2020 | October 2024 | Abandon | 47 | 2 | 0 | Yes | No |
| 16918876 | MULTI-SIDED MATCH MAKING PLATFORMS | July 2020 | August 2024 | Allow | 49 | 6 | 0 | Yes | No |
| 16351230 | PROJECTED FLAP DESIGN | March 2019 | September 2025 | Abandon | 60 | 6 | 0 | Yes | Yes |
| 16351299 | METHOD OF AND SYSTEM FOR IMPAIRMENT RATING REPAIR FOR THE MANAGED IMPAIRMENT REPAIR PROCESS | March 2019 | August 2024 | Allow | 60 | 9 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WEBB, JESSICA MARIE.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner WEBB, JESSICA MARIE works in Art Unit 3683 and has examined 10 patent applications in our dataset. With an allowance rate of 30.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 49 months.
Examiner WEBB, JESSICA MARIE's allowance rate of 30.0% places them in the 4% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by WEBB, JESSICA MARIE receive 4.50 office actions before reaching final disposition. This places the examiner in the 99% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by WEBB, JESSICA MARIE is 49 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +37.5% benefit to allowance rate for applications examined by WEBB, JESSICA MARIE. This interview benefit is in the 85% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 10.0% of applications are subsequently allowed. This success rate is in the 5% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 0.0% of cases where such amendments are filed. This entry rate is in the 3% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
This examiner withdraws rejections or reopens prosecution in 33.3% of appeals filed. This is in the 5% percentile among all examiners. Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 0.0% are granted (fully or in part). This grant rate is in the 6% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 40% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 43% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.